Daily Bio News Summary — 2026-10-19: Three billion-dollar bets, a Phase 3 rebound and a widening retrenchment

Monday’s harvest produced 19 articles across seven of the sources we track, and the shape of the day is unusually clear: capital is moving toward platforms that can be licensed, bought or partnered, while clinical and manufacturing footprints are being trimmed. Three deals account for the headline numbers, two Phase 3/Phase 2 readouts reverse recent setbacks, and four separate items describe companies pulling back — from a lupus study, from headcount, from a country.

Three deals, three different logics

The largest is Roche’s return to Hansoh Pharmaceutical for a $15 billion biobucks antibody-drug conjugate pact, roughly a year after the two companies’ first ADC team-up (Fierce Biotech, 2026-10-19). Biobucks structures front-load optionality rather than cash, so the headline number is best read as a ceiling on milestones rather than money committed on day one; the harvested headline does not disclose the upfront.

Merck KGaA’s $1.3 billion purchase of Silence Therapeutics is the opposite kind of transaction — an outright acquisition of a platform, and one the Fierce Biotech summary explicitly frames as following the British biotech’s mid-stage success for a challenger to Takeda’s Mimrylo (Fierce Biotech, 2026-10-19). That is a useful marker of how quickly a single mid-stage readout can reprice an RNAi platform asset.

The third is Lilly’s partnership with Hong Kong’s Metis TechBio, worth up to $1.1 billion, which gives Lilly access to an AI drug delivery platform; Fierce Biotech notes this is one of a series of partnerships Lilly has accumulated in both drug delivery and AI-based technologies (Fierce Biotech, 2026-10-19). AI here is being bought as infrastructure attached to a delivery problem, not as a discovery engine in the abstract.

Clinical: two rebounds, one repeat failure

Disc Medicine’s bitopertin delivered what Fierce Biotech called “overwhelmingly positive” Phase 3 data, coming after an FDA rejection for the program (Fierce Biotech, 2026-10-19). Whatever the regulatory path ahead, the readout resets a program that had been written down.

AbbVie’s next-generation Crohn’s disease combination candidate beat Skyrizi in a Phase 2 trial (Fierce Biotech, 2026-10-19) — a company-internal comparison that matters commercially because Skyrizi is the incumbent AbbVie itself is selling.

On the regulatory side, Lilly’s Omvoh posted a Phase 3 win in pediatric ulcerative colitis and will seek a pediatric approval, a move the Fierce Pharma summary frames as an attempt to gain an edge in the competitive inflammatory bowel disease market (Fierce Pharma, 2026-10-19). GSK’s B7-H3-targeted ADC ris-rez generated the first data from its international small cell lung cancer trial, backing earlier results from a Chinese study (Pharmaphorum, 2026-10-19). Rigel Pharmaceuticals used ESMO Congress 2026 to present new GAVRETO (pralsetinib) data across RET fusion-positive cancers (PR Newswire, 2026-10-19).

Not every readout went well. EyePoint is halving its workforce after its experimental drug failed a second late-stage trial (Reuters, 2026-10-19), and Enlivex is cutting 60% of staff along with substantial executive salary reductions (Fierce Biotech, 2026-10-19).

Setbacks and retrenchment

Novartis ended a mid-stage Fabhalta study in lupus, insisting there were no efficacy or safety issues, and said it will continue studying the drug in other indications — with late-stage readouts in atypical haemolytic uraemic syndrome and generalized myasthenia gravis expected later this year and next year respectively (BioSpace, 2026-10-19). The disease-level distinction matters: a halted lupus study is not a platform verdict, but it does remove one expansion path from the franchise.

Roche, meanwhile, paused new investments in Germany, joining a group of drugmakers pulling back from the country amid tensions over government healthcare cost-cutting policies (Fierce Pharma, 2026-10-19). Read alongside the manufacturing and headcount items above, the day’s subtext is that site-level capital allocation is being repriced across the sector.

Shareholder pressure also eased at Novavax, where Shah Capital ended its campaign to influence management (Pharmaphorum, 2026-10-19).

Financing and first patients

Two financing items stand out. Nouscom raised €120 million ($135 million) in Series D funds to take a cancer-preventing vaccine through a registration-enabling trial (Fierce Biotech, 2026-10-19) — a late-stage raise for a therapeutic vaccine, a category that has struggled to attract crossover capital. TRexBio’s IPO brought in $116 million to advance its regulatory T cell work (MedCity News, 2026-10-01).

On the clinical-operations side, Servier dosed the first patients in the pivotal Phase 2 EMBLEM-1 cohort of its Phase 1/2 study of Emiltatug Ledadotin in adenoid cystic carcinoma (PR Newswire, 2026-10-19), and Protego Biopharma received FDA IND clearance for a Phase 2/3 study of PROT-001, a small-molecule pharmacological chaperone for AL amyloidosis (PR Newswire, 2026-10-19). Asahi Kasei’s Hovilpri won FDA approval for lesions caused by herpes simplex virus infection — a daily pill that came out of a $919 million acquisition (MedCity News, 2026-10-01).

One research-infrastructure item rounds out the batch: UK Biobank has teamed with industry partners to build what it describes as the world’s most detailed, large-scale picture of the human immune system (Pharmaphorum, 2026-10-19).

What this batch is NOT telling us

Several things a reader might expect on a Monday of this size are absent. There is no large IPO pricing on the day itself — the two IPO/financing items we wrote are a Series D and a completed offering from earlier in the month. There is no megamerger, no Phase 3 oncology topline, and nothing from the cell-and-gene therapy manufacturing layer. We also wrote nothing from STAT News or Endpoints News today: several Endpoints items — including Novartis’s antibiotic approval item, Veradermics’ late-stage hair-loss readout and TriGemX Bio’s SPAC — were behind the soft paywall at fetch time, and no free alternate carried them, so they were dropped rather than linked.

Reading order

1. Merck KGaA / Silence ($1.3B) — the cleanest example today of a mid-stage readout repricing a platform.
2. Disc Medicine bitopertin Phase 3 — a program that was written off now has positive late-stage data.
3. Novartis and Fabhalta — how to read a halted study that the company says is not a safety or efficacy signal.
4. EyePoint and Enlivex — the cost side of failed readouts, in headcount terms.
5. Roche/Hansoh ($15B biobucks) — a reminder that headline deal values and committed cash are different numbers.

How to read the underlying articles

Every item above corresponds to a markdown file in src/content/news/ with pubDate: 2026-10-19 (or 2026-10-01 for the two MedCity pieces). The sourceUrl field in each file points at the original article; description carries the publisher’s own summary where one was retrievable, and the headline verbatim where the publisher blocks automated retrieval.

All items in this batch

1. Roche returns to China’s Hansoh for $15B biobucks ADC pact — Fierce Biotech, 2026-10-19
2. Merck KGaA buys Silence in $1.3B deal for blood cancer drug — Fierce Biotech, 2026-10-19
3. Lilly allies with Metis in $1.1B AI nanoparticle discovery deal — Fierce Biotech, 2026-10-19
4. Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues — BioSpace, 2026-10-19
5. Data reveal is promising for GSK’s lung cancer drug ris-rez — Pharmaphorum, 2026-10-19
6. AbbVie’s next-gen Crohn’s combo beats Skyrizi in ph. 2 test — Fierce Biotech, 2026-10-19
7. Disc spins past FDA setback with ‘overwhelmingly positive’ data — Fierce Biotech, 2026-10-19
8. Lilly’s Omvoh to seek pediatric UC approval — Fierce Pharma, 2026-10-19
9. EyePoint to halve workforce after experimental drug fails second late-stage trial — Reuters, 2026-10-19
10. Enlivex lays off 60% of staff, ‘substantially’ cuts exec pay — Fierce Biotech, 2026-10-19
11. Roche pauses future Germany investments — Fierce Pharma, 2026-10-19
12. Novavax critic Shah Capital ends its activism campaign — Pharmaphorum, 2026-10-19
13. Nouscom bags $135M for pivotal therapeutic cancer vaccine trial — Fierce Biotech, 2026-10-19
14. Servier announces first patients dosed in pivotal Phase 2 EMBLEM-1 cohort — PR Newswire, 2026-10-19
15. Protego announces FDA IND clearance for Phase 2/3 study of PROT-001 in AL amyloidosis — PR Newswire, 2026-10-19
16. Rigel highlights new GAVRETO data across RET fusion-positive cancers at ESMO 2026 — PR Newswire, 2026-10-19
17. UK Biobank partners with industry on ‘most detailed’ immune map — Pharmaphorum, 2026-10-19
18. Asahi Kasei acquisition pays off with FDA approval for novel herpes drug — MedCity News, 2026-10-01
19. TRexBio’s IPO bags $116M to bring the immune system back into balance — MedCity News, 2026-10-01